Inferra AIResearch Tools

Inferra AI / Company / ILMN

Illumina, Inc.

ILMN · Health Care

Last earnings Oct 29, 2026

Key results

Reported revenuequarter

$1.13 billion

Third quarter 2026 results Reported revenue was $1.13 billion for Q3 2026, up 4.2% from Q3 2025.

SEC original ↗Illumina, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Growthquarter

up 4.2%

Third quarter 2026 results Reported revenue was $1.13 billion for Q3 2026, up 4.2% from Q3 2025.

SEC original ↗Illumina, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Revenuequarter

$1.17 billion

Revenue excluding tariff refunds was $1.17 billion, up 4.7% after also excluding the impacts of currency, acquisitions, and the Greater China region ( ROW 1 organic revenue growth ).

SEC original ↗Illumina, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

GAAP operating marginquarter

27.0%

GAAP operating margin was 27.0% and non GAAP operating margin, excluding tariff refunds, was 25.0%.

SEC original ↗Illumina, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

GAAP EPSquarter

$1.43

GAAP diluted EPS was $1.43 and non GAAP diluted EPS, excluding tariff refunds, was $1.44.

SEC original ↗Illumina, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Gross marginquarter

73.5 %

Third quarter results GAAP Non-GAAP (a) Non-GAAP Excluding Tariff Refunds (b) Dollars in millions, except per share amounts Q3 2026 Q3 2025 Q3 2026 Q3 2025 Q3 2026 Revenue $ 1,129 $ 1,084 $ 1,129 $ 1,084 $ 1,166 Gross margin 73.5 % 67.6 % 75.3 % 69.2 % 69.4 % Operating profit $ 305 $ 227 $ 325 $ 265 $ 292 Operating margin 27.0 % 21.0 % 28.8 % 24.5 % 25.0 % Diluted EPS $ 1.43 $ 0.98 $ 1.62 $ 1.34 $ 1.44 (a) See tables in Results of Operations - Non-GAAP section below for GAAP and non-GAAP reconciliations.

SEC original ↗Illumina, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Free cash flowquarter

$41 million

1 R OW rest-of-world, excluding Greater China region due to our inclusion on China s Unreliable Entities List 1 Capital expenditures for free cash flow purposes were $41 million for Q3 2026.

SEC original ↗Illumina, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Capexquarter

$378 million

Free cash flow (cash flow provided by operations less capital expenditures) was $378 million for the quarter, compared to $253 million in the prior year period.

SEC original ↗Illumina, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Research and developmentquarter

$244 million

Research and development 244 229 736 728

SEC original ↗Illumina, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Net incomequarter

$220 million

Net income $ 220 $ 150 $ 561 $ 516

SEC original ↗Illumina, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

EPSquarter

$ 1.43

Diluted $ 1.43 $ 0.98 $ 3.65 $ 3.29

SEC original ↗Illumina, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

AI analysis

Q3 2026 · reported Oct 29, 2026

Based on: Earnings release + parent 8-K — transcript not held

Reported revenue · Q3 2026
$1.13B
EX-99 · Oct 29, 2026
GAAP EPS · Q3 2026
$1.43
EX-99 · Oct 29, 2026
Gross margin · Q3 2026
73.5 %
EX-99 · Oct 29, 2026
Free cash flow · Q3 2026
$41M
EX-99 · Oct 29, 2026

The quarter in charts

Capex & free cash flow

As stated

0133267400$378MCapex Q$41MFree cash flow Q

EX-99 · Oct 29, 2026 Values as labeled in the release.

Headline figures

MetricQ3 2026Prior qtrYear ago
Reported revenue$1.13 billion—$1.06 billion
Growthup 4.2%—down 3%
Revenue$1.17 billion—$1.06 billion
GAAP operating margin27.0%—20.2%
GAAP EPS$1.43—$1.49
Gross margin73.5 %——
Free cash flow$41 million—$30 million
Capex$378 million—$253 million

EX-99 · Oct 29, 2026

Guidance · company-stated

Direction: Raised

Revenue

“Organic revenue growth greater than 4% and ROW organic revenue growth greater than 5%, both unchanged versus prior guidance.”

Classified from the release's primary full-year outlook statement.

Next earningsNo verified date on fileNo date is estimated or imported

Margin

GAAP operating margin27.0%
Gross margin73.5 %

Cash flow & capex

Free cash flow$41M
Capex$378M

Capital allocation

Free cash flow$41M
Capex$378M

1 R OW rest-of-world, excluding Greater China region due to our inclusion on China s Unreliable Entities List 1 Capital expenditures for free cash flow purposes were $41 million for Q3 2026.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Third quarter 2026 results Reported revenue was $1.13 billion for Q3 2026, up 4.2% from Q3 2025

Based on: Earnings release + parent 8-K — transcript not held

Guidance & outlook

Direction: Raised

Revenue: “Organic revenue growth greater than 4% and ROW organic revenue growth greater than 5%, both unchanged versus prior guidance.”

Revenue — Raised (“raising”)
“Based on continued momentum, we are raising our full year revenue and earnings guidance, said Jacob Thaysen, Chief Executive Officer of Illumina.”

Revenue — Reiterated (“unchanged”)
“Organic revenue growth greater than 4% and ROW organic revenue growth greater than 5%, both unchanged versus prior guidance.”

Classified from the release's primary full-year outlook statement.

Capital allocation

1 R OW rest-of-world, excluding Greater China region due to our inclusion on China s Unreliable Entities List 1 Capital expenditures for free cash flow purposes were $41 million for Q3 2026.

SEC original ↗Illumina, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Free cash flow (cash flow provided by operations less capital expenditures) was $378 million for the quarter, compared to $253 million in the prior year period.

SEC original ↗Illumina, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Strategy & priorities

As we continue to execute our strategy, our innovation is broadening the value of the Illumina ecosystem.

SEC original ↗Illumina, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

The company is unable to provide a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP reported financial measures because it is unable to predict with reasonable certainty the impact of items such as acquisition-related costs, fair value adjustments to contingent consideration, gains and losses from strategic investments, asset impairments, restructuring activities, and the ultimate outcome of pending litigation, among others, without unreasonable effort.

SEC original ↗Illumina, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets.

SEC original ↗Illumina, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Risks & headwinds

Revenue excluding tariff refunds was $1.17 billion, up 4.7% after also excluding the impacts of currency, acquisitions, and the Greater China region ( ROW 1 organic revenue growth ).

SEC original ↗Illumina, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

GAAP operating margin was 27.0% and non GAAP operating margin, excluding tariff refunds, was 25.0%.

SEC original ↗Illumina, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

GAAP diluted EPS was $1.43 and non GAAP diluted EPS, excluding tariff refunds, was $1.44.

SEC original ↗Illumina, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Fiscal year 2026 guidance For fiscal year 2026 and excluding tariff refunds, Illumina now expects Total revenue of $4.64-$4.66 billion versus prior guidance of $4.60-$4.64 billion.

SEC original ↗Illumina, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Third quarter results GAAP Non-GAAP (a) Non-GAAP Excluding Tariff Refunds (b) Dollars in millions, except per share amounts Q3 2026 Q3 2025 Q3 2026 Q3 2025 Q3 2026 Revenue $ 1,129 $ 1,084 $ 1,129 $ 1,084 $ 1,166 Gross margin 73.5 % 67.6 % 75.3 % 69.2 % 69.4 % Operating profit $ 305 $ 227 $ 325 $ 265 $ 292 Operating margin 27.0 % 21.0 % 28.8 % 24.5 % 25.0 % Diluted EPS $ 1.43 $ 0.98 $ 1.62 $ 1.34 $ 1.44 (a) See tables in Results of Operations - Non-GAAP section below for GAAP and non-GAAP reconciliations.

SEC original ↗Illumina, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

(b) Excludes the impacts of International Emergency Economic Powers Act (IEEPA) tariff refunds expected to be recovered, consisting primarily of a $79 million benefit recognized as a reduction to cost of revenue in Q3 2026 and a reduction to revenue of $37 million for the portion of tariff refunds that we expect to credit to customers.

SEC original ↗Illumina, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

What changed vs prior quarter

Growth — prior quarter passage and this quarter's passage are both cited.

SEC original ↗Illumina, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Revenue — prior quarter passage and this quarter's passage are both cited.

SEC original ↗Illumina, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

GAAP operating margin — prior quarter passage and this quarter's passage are both cited.

SEC original ↗Illumina, Inc. — Earnings release (8-K exhibit)EX-99Oct 29, 2026

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareJohnson & Johnson (JNJ) Health Care
Documents

Filings

65 documents

Earnings releases

53 documents

Presentations

0 documents

No presentations for Illumina, Inc. are held in this edition of the library.

Transcripts

0 documents

No transcripts for Illumina, Inc. are held in this edition of the library.

Mentioned by

4 companies

Other tracked companies whose held documents mention Illumina, Inc. by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.